ArticleGynecologic oncology reports2026
Sequential Yttrium-90 radioembolization integrated with multimodal therapy for platinum-resistant ovarian cancer liver metastases.
Article in Gynecologic oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatic metastases from ovarian cancer are associated with poor prognosis, particularly in patients with platinum-resistant disease, and treatment options are limited. We present a case illustrating the feasibility and potential benefit of sequential locoregional therapy using yttrium-90 radioembolization for liver-dominant metastatic ovarian carcinoma. Case Presentation: A 62-year-old female with stage IVB high-grade serous ovarian carcinoma and unresectable hepatic metastases underwent neoadjuvant platinum chemotherapy followed by selective internal radiation therapy targeting dominant liver lesions. Therapy was repeated in a staged manner alongside non-platinum systemic therapy, cytoreductive surgery, and nodal radiation as clinically indicated. Imaging and functional assessments were used to evaluate tumor response and liver function throughout treatment.Sequential radioembolization achieved durable hepatic disease control over a two-year period. The treated right hepatic lobe underwent gradual atrophy with compensatory hypertrophy of the left lobe, preserving overall liver function and enabling repeated therapy. Integration with systemic therapy and surgery allowed continued management of peritoneal disease. Treatment was well tolerated, with manageable laboratory and clinical toxicities. Imaging demonstrated a significant reduction in tumor size and resolution of metabolic activity, supporting effective locoregional control. Conclusion: Sequential yttrium-90 radioembolization is a feasible and potentially durable locoregional strategy for patients with unresectable, platinum-resistant ovarian cancer liver metastases. When integrated with systemic therapy and surgery, this approach may provide meaningful disease control while preserving liver function. Prospective studies are warranted to further define patient selection, optimal sequencing, and clinical outcomes for this emerging therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.